The quarter was better on earnings than on sales. Adjusted EPS was $2.59, above the published consensus of roughly $2.52, while revenue of $1.493 billion was slightly below the roughly $1.51 billion expectation.
| Metric | Q1 FY2027 | Q1 FY2026 / prior expectation |
|---|---|---|
| Revenue | $1,492.7M (Financial Highlights) | $1,391.1M; ~ $1.51B consensus |
| Adjusted diluted EPS | $2.59 (Adjusted results reconciliation) | $2.34; ~ $2.52 consensus |
| Constant-currency organic revenue growth | 6.2% (Organic growth table) | FY2027 target: 6%–7% |
| Operating cash flow | $367.1M (Cash Flow statement) | $420.0M |
| Free cash flow | $279.6M (Free Cash Flow table) | $326.5M |
| FY2027 adjusted EPS guidance | $11.10–$11.30 (FY2027 Outlook) | Unchanged |
| FY2027 capital expenditures | ~$450M (FY2027 Outlook) | Prior: ~$375M |
| FY2027 free-cash-flow guidance | ~$800M (FY2027 Outlook) | Prior: ~$850M |
Underlying demand remained solid, but the mix was uneven. Healthcare delivered the strongest contribution, with revenue up 8% and operating income up to $260.2 million from $235.5 million; recurring consumables and service revenue grew 9% and 10%, respectively (Segment results — Healthcare). Life Sciences also grew well, with revenue up 9% and constant-currency organic growth of 7.9% (Segment results — Life Sciences). AST revenue rose 6%, but its capital-equipment revenue fell 13%, making that segment's growth more dependent on services (Segment results — AST).
Management did not raise the earnings bar. Full-year revenue, organic-growth, and adjusted-EPS guidance were reiterated at 7%–8% reported revenue growth, 6%–7% constant-currency organic growth, and $11.10–$11.30 adjusted EPS (FY2027 Outlook). That makes the quarterly EPS beat helpful but not a clear change to the broader earnings picture.
Cash generation is the main negative surprise. First-quarter operating cash flow fell to $367.1 million from $420.0 million and free cash flow fell to $279.6 million from $326.5 million (Cash Flow statement; Free Cash Flow table). More importantly, the North Carolina chemistry facility investment lifted expected annual capital expenditures by $75 million, forcing free-cash-flow guidance down by $50 million to approximately $800 million (FY2027 Outlook). The company frames the investment as capacity and productivity improvement, but the near-term financial effect is higher spending and lower cash conversion.
The restructuring adds execution risk without changing adjusted EPS guidance today. STERIS expects $55 million–$70 million of pre-tax charges, including $40 million–$50 million of cash costs, spread through fiscal 2030 (Consolidation Plan). Because the charges will be excluded from adjusted earnings, they do not alter the stated EPS outlook; however, the long implementation timeline and facility closures mean the promised operational benefits remain unproven.
Net read: mixed rather than decisively positive. The adjusted-EPS beat and strong Healthcare performance were offset by a modest revenue shortfall, weaker quarterly cash flow, a lower free-cash-flow target, and newly quantified restructuring costs. The filing improves confidence in near-term margins and demand, but it does not lift the full-year earnings expectation.
Read the original 8-K on SEC EDGAR ↗